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Erythropoietin (EPO) exerts (renal) tissue protective eﬀects. Since it is unclear whether this is a direct eﬀect of EPO on the kidney
or not, we investigated whether EPO is able to protect human renal tubular epithelial cells (hTECs) from oxidative stress and if
so which pathways are involved. EPO (epoetin delta) could protect hTECs against oxidative stress by a dose-dependent inhibition
of reactive oxygen species formation. This protective eﬀect is possibly related to the membranous expression of the EPO receptor
(EPOR) since our data point to the membranous EPOR expression as a prerequisite for this protective eﬀect. Oxidative stress
reduction went along with the upregulation of renoprotective genes. Whilst three of these, heme oxygenase-1 (HO-1), aquaporin-
1 (AQP-1), and B-cell CLL/lymphoma 2 (Bcl-2) have already been associated with EPO-induced renoprotection, this study for
the ﬁrst time suggests carboxypeptidase M (CPM), dipeptidyl peptidase IV (DPPIV), and cytoglobin (Cygb) to play a role in this
process.
1.Introduction
Oxidative stress occurs when there is an imbalance between
the generation of reactive oxygen species (ROS) and a
biological system’s ability to detoxify the reactive interme-
diates or repair the resulting damage [1], and is associ-
ated with processes such as infection, inﬂammation, and
ischemia/reperfusion injury (IRI) [2]. To minimize ROS-
induced damaging eﬀects, aerobic organisms developed
antioxidant defense mechanisms to counteract the oxidant
eﬀects. Besides endogenous molecules, the protective eﬀect
of various exogenous compounds against oxidative stress has
also been investigated [3, 4]. Recombinant erythropoietin
(EPO) is one of these exogenous compounds and has been
found to possess antioxidant properties in addition to its
original hematopoietic function [5].
Although it is known that EPO is able to attenuate (acute
and chronic) kidney failure [6], it is not yet clear whether
this is the result of a direct eﬀect of EPO on renal (tubular)
cells or of a systemically EPO-induced eﬀect. Therefore,
it was investigated in the present in vitro study whether
the renoprotective eﬀects of EPO can, at least to a certain
extent, be explained by a direct, antioxidant eﬀect of EPO
on the renal (tubular) cells. More precisely the eﬀect of EPO
(epoetin delta, a recombinant EPO molecule produced in
a human cell line through gene-activation technology) on
glucose oxidase (GO)-induced oxidative stress in primary
cultures of human renal tubular epithelial cells (hTECs) was
evaluated.
As a next step, we investigated (i) whether the EPO
receptor (EPOR) is involved herein, (ii) the contribution
of genes previously linked to EPO-induced protective
mechanisms, such as heme oxygenase-1 (HO-1), aquaporin-
1 (AQP-1), and B-cell CLL/lymphoma-2 (Bcl-2), and (iii)
a possible role for carboxypeptidase M (CPM) dipeptidyl
peptidase IV (DPPIV) and cytoglobin (Cygb) genes not yet
linked to EPO-induced renoprotective mechanisms but to
oxidative stress in general.2 Journal of Biomedicine and Biotechnology
2.MaterialandMethods
2.1. Culture of Primary Human Tubular Kidney Cells. Pri-
mary hTECs were isolated as previously described [7, 8].
Brieﬂy, normal human kidney tissue, that became available
through nephrectomies performed on oncological indica-
tion, was collected and processed in a sterile manner. The use
of this tissue for the purpose of cell culture was approved by
the Local Ethical Committee. Macroscopically normal tissue
was decapsulated. Tissue from cortex and outer stripe of
outermedullawasdissected,cutintopiecesofapproximately
1mm 3, and digested in collagenase D solution. The suspen-
sion was shaken vigorously for 2 hours at 37◦Ca n ds i e v e d
through a 120μm sieve. The resulting single-cell suspension
was loaded on top of a discontinuous Percoll gradient with
densities of 1.04 and 1.07g/mL. After centrifugation, tubular
cells were carefully aspirated, washed, and brought into
culture on 48-well plates or glass coverslips in α-minimal
essential medium (α-MEM) modiﬁed according to Gibson-
D’Ambrosio [9] and supplemented with 10% of fetal calf
serum. Fetal calf serum-containing medium was replaced by
serum-free, Gibson-d’Ambrosio-modiﬁed α-MEM medium
24 hours before performing the experiments.
2.2. Administration of Epoetin Delta and Epoetin Alfa.
Conﬂuent hTECs were incubated with diﬀerent concen-
trations of epoetin delta (Dynepo, Shire Pharmaceuticals
Ltd.; 0–5–100IU/mL) or epoetin alfa (Eprex, Janssen-Cilag;
100IU/mL) for 24 hours before or concomitantly with the
induction of oxidative stress (at least 4 wells per condition).
2.3. Induction of Oxidative Stress by GO. Oxidative stress was
inducedbyexposureofconﬂuenthTECstodiﬀerentconcen-
trations of GO (Sigma; 0–0.1–1–5–10–50–100IU/mL) for
diﬀerent time periods (20 minutes, 30 minutes, 40 minutes,
1 hour, 2 hours, 3 hours, and 4 hours) [3, 10].
2.4. Measurement of Oxidative Stress. The GO-induced
oxidative stress, assessed as the amount of generated
cellular radicals, was measured by the 2 ,7 -dichlorod-
ihydroﬂuorescein diacetate (H2DCFDA, Sigma) molecule.
H2DCFDA is metabolized to nonﬂuorescent DCFA by
intracellular esterases and to ﬂuorescent DCF by free oxygen
radicals. DCF ﬂuorescence was measured using ﬂuorometry
at excitation and emission wavelengths of 485nm and
535nm, respectively.
2.5. RNA Isolation and Quantitative Real-Time RT-PCR.
The mRNA expression of HO-1, AQP-1, Bcl-2, CPM,
D P P I V ,a n dC y g bi nh T E C sw a sa n a l y z e db ym e a n so f
the quantitative real-time reverse transcription-polymerase
chain reaction (real-time RT-PCR) using the ﬂuorescent
TaqMan methodology and the ABI Prism 7000 Sequence
Detection System (Applied Biosystems). According to the
manufacturer’s instructions, cDNA was synthesized from
total RNA extracted with the High Pure RNA Isolation
Kit (Roche) using the High-Capacity cDNA Archive kit
(Applied Biosystems). Ready to use, predesigned, primer and
probe sets (Applied Biosystems)for human genes of inter-
est (Hs00157965 m1 for HO-1, Hs00166067 m1 for AQP-
1, Hs00153350 m1 for Bcl-2, Hs00266395 m1 for CPM,
Hs00175210 m1 for DPPIV, Hs00370478 m1 for Cygb) and
thehousekeepinggeneGAPDH(Hs99999905 m1)wereused
according to the manufacturer’s guidelines. The mRNA
quantity of the investigated genes was analyzed in triplicate,
normalized against GAPDH, and expressed in relation to a
calibrator sample using the comparative Ct method. Control
cell cultures, that is, cultures receiving neither GO nor
epoetindeltaservedasthecalibratorsample,whichwasgiven
a gene of interest/GAPDH mRNA expression ratio of 1.
2.6. Erythropoietin Receptor Immunoﬂuorescence. Conﬂuent
hTECs were ﬁxed in 4% formaldehyde for 10 minutes.
Cells were incubated overnight with the M-20 anti-EPOR
antibody (Santa Cruz Biotechnology) and subsequently with
FITC-labeled goat anti-rabbit IgG antibody during 2 hours.
Sections in which the primary antibody was omitted served
as negative control.
2.7. Study Setup and Statistical Analysis. Because of the
interindividual variation in DCF ﬂuorescence and mRNA
expression levels of some investigated genes in cell mono-
layers derived from individual kidney samples, some data
arerepresentedassinglerepresentativeexperiments.Dataare
presentedasmean ±SD.StatisticswereperformedwithSPSS
16.0. Comparisons between the study groups for each time
point and/or GO dose were assessed using a Kruskal-Wallis
test, followed by a Mann-Witney U-test in combination
with Bonferroni correction when more than two groups
were compared. Statistical comparison of mean values of
quantitative real-time RT-PCR analyses was performed with
GraphPad Prism 3.0 software (GraphPad Software Inc., San
Diego, CA, USA) using a Student’s t-test in combination
with Bonferroni correction when more than two groups
were compared. P-values <. 05 were considered statistically
signiﬁcant.
3. Results
3.1. Induction of Oxidative Stress by GO. Quantiﬁcation of
oxidative stress resulting from the addition of GO to hTECs
at diﬀerent concentrations (0 to 100IU/mL) and time points
(10 to 240 minutes) shows that incubation of hTECs with
GO resulted in a concentration-dependent accumulation of
ROS during time (Figure 1).
3.2. Eﬀect of Epoetin Delta on the GO-Induced Oxidative
Stress. Preincubation of hTECs with epoetin delta (24 hours
before addition of GO; 0–0.1–1–10IU/mL) signiﬁcantly
protects the cells against oxidative stress as indicated by a
dose-dependent, attenuated ROS production. Furthermore,
it was found that epoetin delta added to the culture
mediumconcomitantlywiththeinductionofoxidativestress
attenuated the formation of ROS as well, be it in a less
pronounced way. The epoetin delta-induced eﬀects on ROS
formation were only observed in 6 out of 9 experiments
(hTECs cultures of 9 diﬀerent kidney specimens) (Figure 2).Journal of Biomedicine and Biotechnology 3
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Figure 1: Induction of oxidative stress in conﬂuent hTECs by
incubation with GO (0 to 100IU/mL) during 0 to 240 minutes. By
measuring DCF ﬂuorescence, a concentration-dependent accumu-
lation of ROS was observed during the time.
3.3. Comparison of Epoetin Delta and Epoetin Alfa. Since
epoetin delta did not reduce ROS formation in all hTECs
cultures, it was investigated whether this was due to either
cell culture and/or EPO characteristics. This was done by
comparingtheeﬀectsofepoetindeltatotheseofepoetinalfa.
Itbecameclearthattheoutcomeofthesetwoerythropoiesis-
stimulating agents (ESA) was similar as both of them either
or not protected the same cell cultures from oxidative stress
(Figure 3).
3.4. Expression of the Erythropoietin Receptor in Human
Tubular Epithelial Cells. As epoetin delta and alfa induced
similar eﬀects on oxidative stress in the same culture,
the presence or absence of protective mechanisms must
be due to culture characteristics. Because EPO exerts its
actions via the EPOR, its expression was investigated in
two diﬀerent cultures: one of them showing epoetin delta-
induced protection whereas the other did not. In protective
as well as nonprotective cultures, EPOR expression was
seen in intracellular vesicles (Figure 4). However, only in
the culture that showed EPO-induced protection against
oxidative stress, EPOR expression could be found at the level
of the plasma membrane (Figure 4(a)). Data from additional
experiments learned that membranous EPOR expression is
only present in highly conﬂuent cultures (data not shown).
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Figure 2: GO-induced oxidative stress (240 minutes) in hTECs
either pre/coincubated with epoetin delta or not. Epoetin delta
attenuated oxidative stress in a dose-dependent way by reducing
ROS formation. The data are expressed as the mean ± SD of 4
monolayers per condition from a single experiment representative
of 6 separate experiments. ∗P<. 05, ◦P<. 01 compared to the
control.
3.5. mRNA Expression of Genes Already Known to Be Involved
in the Protective Eﬀects of Erythropoietin. In the present
study, the mRNA expression of HO-1, AQP-1, and Bcl-2
was assessed in cultures that were either preincubated with
epoetin delta before the induction of oxidative stress or not.
Under basal conditions (no GO incubation), precondition-
ing of hTECs with epoetin delta (100IU/mL) resulted in a
signiﬁcant upregulation of HO-1 (1.00 ± 0.31 versus 1.56
± 0.37, P<. 05) and AQP-1 (1.00 ± 0.03 versus 2.26
± 0.12, P<. 05) mRNA expression. During GO-induced
oxidative stress (1IU/mL), cultures which were preincubated
with epoetin delta (100IU/mL) showed a further increase in
mRNAexpressionofallthreegenesinvestigatedascompared
to cultures which were not preincubated with epoetin delta,
reaching maximum values 60 minutes after the induction of
oxidative stress (HO-1: 1.07 ± 0.20 versus 1.48 ± 0.19; AQP-
1: 1.61 ± 0.11 versus 3.18 ± 0.22; Bcl-2: 0.97 ± 0.18 versus
1.58 ± 0.40; P<. 05) (Figure 5). Interestingly, in cultures
in which no epoetin delta-protective eﬀect against oxidative
stresswasseenalsonoepoetin delta-inducedupregulationof
the genes under study could be observed (data not shown).4 Journal of Biomedicine and Biotechnology
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Figure 3: Comparison of epoetin delta- and epoetin alfa-induced eﬀects on GO-induced oxidative stress (240 minutes) in cell cultures
originating from two diﬀerent kidney specimens, one showing EPO-induced anti-oxidative eﬀects (a) and one where neither epoetin delta
nor epoetin alfa had any eﬀect on oxidative stress (b). Both ESA’s showed a similar eﬀect on GO-induced oxidative stress: either they were
both able to reduce the amount of ROS formed or not. The data are expressed as the mean ± SD of 4 monolayers per condition from a single
experiment representative of 2 separate experiments. ∗P<. 05 compared to the control.
(a) (b)
Figure 4: Immunoﬂuorescent staining of EPOR in two cultures of hTECs that show an epoetin delta-induced eﬀect on oxidative stress
(a) or not (b). EPOR signal is visualized using the M-20 anti-EPOR antibody and an FITC-labeled (green ﬂuorescence) secondary antibody.
Punctate intracellular staining is seen in bothcultures while membranous stainingis only seen in cultures that showed epoetin delta-induced
eﬀects on oxidative stress.
3.6. Eﬀect of Epoetin Delta on the Expression of CPM, DPPIV,
and Cygb. Figure 6 shows that preconditioning of hTECs
with epoetin delta (100IU/mL) resulted in a signiﬁcant
increase of CPM (1.00 ± 0.10 versus 2.09 ± 0.30, P<. 05)
and DPPIV (1.00 ± 0.24 versus 1.77 ± 0.56, P<. 05)
mRNA expressions . During GO-induced oxidative stress
(1IU/mL), cultures which were preincubated with epoetin
delta (100IU/mL) showed a further increase in mRNA
expression of all three genes investigated as compared to
cultures which were not preincubated with epoetin delta,
reaching maximum values 60 minutes after the induction
of oxidative stress (CPM: 1.19 ± 0.13 versus 3.56 ± 0.77;
DPPIV: 1.12 ± 0.21 versus 2.61 ± 0.40; Cygb: 2.22 ± 0.37
versus 3.41 ± 0.43; P<. 05). Again, this upregulation was
only observed in cultures in which epoetin delta exerted a
protective eﬀect against oxidative stress; that is, in cultures
in which ROS production was suppressed as compared to
controls. In cultures in which epoetin delta did not show
protective eﬀects, no upregulation of CPM, DPPIV, or Cygb
was observed (CPM: 1.00 ± 0.03 versus 0.81 ± 0.13; DPPIV:
1.00 ± 0.14 versus 0.89 ± 0.14; Cygb: 1.00 ± 0.29 versus 0.87
± 0.29; NS) (Figure 6).Journal of Biomedicine and Biotechnology 5
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Figure 5: Quantitative real-time RT-PCR analysis of HO-1 (a), AQP-1 (b), and Bcl-2 (c) expressions in mixed hTECs under basal conditions
andafterGO-inducedoxidativestress(1IU/mL)eitherornotinthepresenceofepoetindelta(100IU/mL).GAPDHwasusedasendogenous
control housekeeping gene. Preconditioning the cells with EPO resulted in a signiﬁcant upregulation of HO-1 and AQP-1 mRNA. GO-
induced oxidative stress further increased HO-1, AQP-1, and Bcl-2 mRNA expressions with maximum levels 60 minutes after induction of
oxidative stress. Data are presented as the mean ± SD of triplicate determinations of 2 runs (i.e., 6 values each). ∗P<. 05 versus no GO,
◦P<. 05 versus epoetin delta 0IU/mL, #P<. 05 versus 30 minutes GO incubation.
4. Discussion
In the present study, oxidative stress was induced using
glucose oxidase (GO), an enzyme that, in the presence
of glucose, produces H2O2, the most important source
of cellular ROS. We showed that GO indeed induced a
concentration-dependent accumulation of ROS in primary
hTECs during time. Pretreatment of the primary hTECs
with epoetin delta (5 or 100IU/mL) resulted in a statistically
signiﬁcant reduction of GO-induced ROS production. As
this eﬀect was less pronounced when epoetin delta was
administered together with GO, one may assume that
EPO (epoetin delta) exerts a direct eﬀect on renal tubular
cells by (pre)conditioning these cells towards protection.
Interestingly, epoetin delta pretreatment did not protect
against oxidative stress in all cultures investigated. In further
experiments, we found that epoetin delta and epoetin alfa
(a widely used ESA, known to have renoprotective eﬀects
both in vivo [11] and in vitro [12]) acted in the same way;
that is, both compounds were either protective or not when
administered to the same cultures.
In an attempt to explain this intriguing ﬁnding, the
EPOR expression was investigated in these cell cultures using
the M-20 antibody, recently identiﬁed as a speciﬁc anti-
EPOR antibody [13]. Since nonerythropoietic properties
of EPO most likely are also mediated by EPOR [14, 15], its
membranous expression is a prerequisite for a culture to be
able to respond to EPO. Interestingly, it was observed that in
a culture showing a protective EPO-induced response, EPOR
staining was present both in intracellular vesicles and at the
level of the plasma membrane, while in a nonresponsive
culture, the EPOR signal was conﬁned to intracellular
vesicles. Further studies showed that membranous EPOR
expression is only present in highly conﬂuent cultures.
Hence, it was concluded that culture characteristics, more
speciﬁcally diﬀerent levels of conﬂuence, going along
with the presence and/or absence of membranous EPOR
expression, speciﬁc characteristics of the kidney donor, as
well as the fact that some cell cultures themselves seemed
to have better anti-oxidative mechanisms than others (cfr.
Figure 3) could contribute to the interesting observation
that EPO-mediated anti-oxidative eﬀects are not seen in all
cell cultures investigated.
Inordertotrytoidentifysomespeciﬁcpathwaysthrough
which EPO could exert these observed anti-oxidative eﬀects,
the EPO-induced eﬀects on HO-1, AQP-1, and Bcl-2 mRNA
were investigated. These three genes have already intensively
been studied in in vivo experimental setups and in line with
previousstudiesperformedinourlaboratory[16],precondi-
tioning of hTECs with epoetin delta resulted in a signiﬁcant
upregulation of HO-1 and AQP-1 mRNA expressions.
Induction of HO-1 (or HSP32), known as a protein
with antiapoptotic, anti-inﬂammatory, and cytoprotective
properties [17], and its tissue protective eﬀects are frequently
seeninseveralmodelsofrenalinjury[18,19].EPO-mediated
renoprotectiveeﬀectsinvivoaswellasinvitrohavebeenpar-
tially attributed to the renal upregulation of HO-1 [16, 20].
One of the mechanisms by which increased HO-1 expression6 Journal of Biomedicine and Biotechnology
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Figure 6: Comparison of the relative (normalized to GAPDH and to calibrator sample) expressions of CPM (a), DPPIV (b), and Cygb (c)
under basal conditions and after GO-induced oxidative stress (1IU/mL) in cell cultures originating from two diﬀerent kidney specimens,
one showing EPO-induced anti-oxidative eﬀects and one without any eﬀect of EPO on oxidative stress. Preconditioning the cells with EPO
resulted in a signiﬁcant upregulation of CPM and DPPIV, mRNA. GO-induced oxidative stress further increased CPM, DPPIV and Cygb
mRNA expressions with maximum levels 60 minutes after induction of oxidative stress. Remarkably, the cell culture in which epoetin delta
wasnotabletoinduceaprotectiveeﬀectagainstoxidativestresswasalsonotabletoinduceupregulationofthosemRNA’s.Dataarepresented
as the mean ± SD of triplicate determinations representative of 2 separate runs (i.e., 6 values each). ∗P<. 05 versus no GO, ◦P<. 05 versus
epoetin delta 0IU/mL.
may contribute to cytoprotection is by catalyzing the degra-
dation of prooxidant heme to the radical scavengers ferritin,
biliverdin, and bilirubin [21].
T h ec y t o p r o t e c t i v ee ﬀects of EPO preconditioning have
also been linked to the prevention of renal IRI-induced
downregulation of AQP-1 [11], a major transmembranous
water channel in cell plasma membranes of the renal proxi-
mal tubule and the descending limb of Henle’s loop playing
a role in urine concentration [22]. We could conﬁrm these
results in that we were able to demonstrate a direct (upreg-
ulatory) eﬀect of EPO on one of the renal tubular transport
proteins present in the kidney. Moreover, our experiments
for the ﬁrst time showed that epoetin delta administration
signiﬁcantly upregulated the AQP-1 expression in primary,
GO-treated hTECs, which is in line with the recent observa-
tionthatAQP-1actsasanO2 transporter,therebyfacilitating
O2 diﬀusion across the cell membrane [23].
In agreement with the observation that EPO exerts
antiapoptotic eﬀects and that Bcl-2 has been reported to be
involved in several models of kidney injury [24, 25], Bcl-
2 mRNA expression was also signiﬁcantly upregulated in
EPO-treated hTECs, under basal conditions as well as afterJournal of Biomedicine and Biotechnology 7
GO-induced oxidative stress, hereby pointing to a role for
Bcl-2 in the EPO-mediated cell protection against GO-
induced oxidative stress.
Interestingly, the epoetin delta-induced upregulation of
HO-1, AQP-1, and Bcl-2 expression could only be observed
in cell cultures in which the compound induced an attenua-
tion of ROS production again pointing to a direct protective
eﬀect on the tubular cells.
As we also aimed to get further insight into the mecha-
nisms underlying EPO-induced antioxidant cytoprotection,
expressions of three other genes potentially involved in the
protectiveprocesswereinvestigated:CPM,DPPIV,andCygb.
E p o e t i nd e l t at r e a t m e n tr e s u l t e di na nu p r e g u l a t i o no ft h e s e
genes under basal conditions, which was further increased in
cellculturesthatshowedanepoetindelta-inducedprotection
against GO-induced oxidative stress (and not in cultures that
did not show this protection). Although data of the present
study do not allow drawing clear-cut conclusions about a
role for CPM, DPPIV, and Cygb in the EPO’s anti-oxidative
properties, the observed EPO-induced alterations in their
mRNA expression are worth being considered in view of the
already known functions mentioned below.
CPM is a membrane glycoprotein which speciﬁcally
removes C-terminal basic residues from peptides and pro-
teins [26, 27]. The wide distribution of CPM in human
tissues,includingthekidneyandtherecentﬁndingthatCPM
w o u l db ei n v o l v e di ni n ﬂ a m m a t o ryp r o c e s s e s[ 28]p r o m p t e d
us to study the eﬀects of EPO on its expression. Although
previous experiments have indicated that CPM is expressed
in both the mammalian kidney [27] and in Madin-Darby
canine kidney (MDCK) cells [29], we demonstrated for the
ﬁrst time that (i) CPM is expressed in primary cultures of
hTECs and (ii) CPM expression is associated with EPO-
induced cytoprotection against oxidative stress. Related to
these results, literature has mentioned that CPM expression
on extravillous trophoblasts is partially regulated by tissue
oxygen concentration, and higher oxygen concentrations
(20%) could induce CPM expression [30].
DPPIV is the most intensively studied member of the
proline-speciﬁc dipeptidyl peptidase (DPP) family. Widely
expressedamongorgansandbodyﬂuidsandhavingdiﬀerent
substrates in diﬀerent organs [31] ,ab r o a dr a n g eo fp o t e n t i a l
functions have been attributed to DPPIV. Inhibitors of
DPPIV are used in the treatment of dysglycemia [32], limit
IRI in the lung [33], and abrogate acute organ rejection in
lungandhearttransplantationmodels[34,35].SinceDPPIV
is expressed on the brush border of PTC [36], by far the most
vulnerable cells during ischemic injury, it is of particular
interest to investigate potential anti-oxidative eﬀects of EPO
on this DPPIV expression in these cells.
Both being cell surface peptidases, CPM and DPPIV
have a lot in common and are frequently studied together
[37]. In our study, the responses of these two peptidases
to GO-induced oxidative stress and EPO-induced protective
eﬀects are similar. After EPO administration, these two genes
are upregulated concomitantly with EPOR expression at
the cell membrane, which might indicate that CPM and
DPPIV may be involved in the EPO-mediated anti-oxidative
eﬀects.
Cygb, sharing a common ancestry with myoglobin, is a
recently discovered member of the vertebrate globin family
[38] and is expressed in many diﬀerent tissues at varying
levels [39, 40]. Evidence has been provided for Cygb to be a
hypoxia-induced gene which is transcriptionally upregulated
during chronic hypoxia in a hippocampal neuronal cell line
[38] and ﬁbroblast cell lineage [41]. More or less in line with
the ﬁndings of the present study it has been demonstrated
that Cygb may reduce the induction of intracellular ROS
formation [42]. Xu’ss t u d y[ 43]i nr a th e p a t i cs t e l l a t ec e l l s
also provides evidence that overexpression of Cygb could
protect cells against oxidative stress both in vitro and in vivo.
Data of our study for the ﬁrst time demonstrate that Cygb (i)
is expressed in primary hTECs, (ii) is upregulated after EPO
administration,and(iii)mayplayaroleinthemechanism(s)
underlying EPO-induced anti-oxidative eﬀects. Interestingly,
recently we also demonstrated Cygb to be expressed at the
protein level in renal tissue (data not shown).
5. Conclusions
In the present work, evidence was found for a direct cyto-
protective eﬀect of epoetin delta on renal tubular cells.
This EPO-induced eﬀect on renal tubular cells may be an
important contribution to the EPO-induced renal protective
eﬀect seen in vivo. Furthermore, comparison of the localiza-
tion of the EPOR in EPO-responding versus nonresponding
cultures allows to suggest that the cytoprotective eﬀect of
epoetin delta in primary hTECs is mediated by the EPOR.
Interestingly, the expression of six genes under study was
signiﬁcantly upregulated upon EPO administration in and
onlyinthosecellculturesinwhichanEPO-inducedcytopro-
tective eﬀect was seen, allowing (i) to conﬁrm a role of HO-
1, AQP-1, and Bcl-2 in the EPO-induced preconditioning
of cells and (ii) to speculate about a role of CPM, DPPIV,
and Cygb in this process. Further research with regard to
the eﬀects of EPO on the protein expression and function
of these proteins is warranted.
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